Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab vs Azathioprine in NMO-SD
NCT03002038Phase 3Completed
- Start
- Sep 2015
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (2 arms). Primary endpoint: Annual Relapse Rate at 1 year. Started Sep 2015; status: completed.
02
Drugs
rituximab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT03002038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002038.